<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122534">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01690572</url>
  </required_header>
  <id_info>
    <org_study_id>DEBT</org_study_id>
    <nct_id>NCT01690572</nct_id>
  </id_info>
  <brief_title>Drug Eluting Balloon for Prevention of Constrictive Remodeling</brief_title>
  <official_title>Drug Coated Balloon (DCB) for the Prevention of Constrictive Remodeling and Restenosis in Small Vessel Coronary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Christoph Hehrlein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herz-Zentrums Bad Krozingen</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Earlier studies indicated that Percutaneous coronary intervention (PCI) may be problematic
      in diffuse small vessel disease especially of diabetic patients. High restenosis rates after
      balloon only procedures in small vessels occur due to negative constrictive vessel
      remodeling if DES (drug eluting stents) are not used and prolonged anti-platelet therapy is
      not indicated. The main hypothesis of the trial is that in analogy to DCB success in
      peripheral arterial disease (PAD), cellular toxicity of the drug paclitaxel eluting from a
      IN.PACT FalconTM DCB will prevent constrictive remodelling of small coronary vessel segments
      after dilatation. The IN.PACT FalconTM DCB is compared with plain old balloon angioplasty
      (POBA) using a Sprinter LegendTM balloon in small vessel coronary artery disease. A
      constrictive remodelling process will be measured by optical coherence tomography (OCT) at 9
      months median F/U. This pilot trial is planned to be randomized 1:1 for DCB against POBA
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>MACE-rate</measure>
    <time_frame>12 months after initial treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>combined end-point: death, myocardial infarction and revascularisation of the target lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OCT-measurement</measure>
    <time_frame>during follow-up, after 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>each symptomatic patient will be examined using optical coherence tomography to detect, if the symptoms are caused by a narrowing at the target lesion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Paclitaxel coated balloon catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel coated balloon catheter &quot;IN.PACT Falcon&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>uncoated balloon catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>uncoated balloon catheter &quot;sprinter legend&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel coated balloon catheter</intervention_name>
    <description>Dilatation of the target lesion</description>
    <arm_group_label>Paclitaxel coated balloon catheter</arm_group_label>
    <other_name>IN.PACT Falcon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>uncoated balloon catheter &quot;sprinter legend&quot;</intervention_name>
    <description>Dilatation of the target lesion</description>
    <arm_group_label>uncoated balloon catheter</arm_group_label>
    <other_name>sprinter legend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least one target lesion with a stenosis severity ≥ 50% in one coronary segment
             with a diameter ≤ 2.5 mm

          -  age &gt; 18 years

          -  weight &gt; 45 kg

          -  patient suitable for balloon dilatation and not suitable for elective implantation of
             a drug eluting stent

          -  insulin-dependent or non-insulin-dependent diabetes mellitus

          -  length of lesion ≥ 15 mm

        Exclusion Criteria:

          -  Life expectancy &lt; 12 months

          -  In-Stent restenosis

          -  planned coronary bypass or heart valve OP

          -  ST elevation myocardial infarction within the last 72 hours

          -  cardiogenic shock

          -  renal impairment or liver dysfunction (creatinine &gt; 2.0 mg/dl, AST/ALT &gt; 3x of normal
             value

          -  malcompliance

          -  pregnant or breastfeeding women or women who like to be pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Hehrlein, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology and Angiology I, Heart Center, Freiburg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology and Angiology I, Heart Center,</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Weis</last_name>
      <phone>0049 7641 270 77090</phone>
      <email>christoph.weis@universitaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Hehrlein, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 5, 2012</lastchanged_date>
  <firstreceived_date>September 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herz-Zentrums Bad Krozingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Christoph Hehrlein</investigator_full_name>
    <investigator_title>Professor Dr. med.</investigator_title>
  </responsible_party>
  <keyword>drug eluting balloon</keyword>
  <keyword>constrictive remodeling</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
